Table 2.

Details of A. baumannii isolates, by sequence type

				Non-susceptible to (%):							Resistant determinants
ST	No.	Allelic profile	Time course	IPM	TZP	TCC	CAZ	AMK	LVX	MNO
191	32	1-3-3-2-2-94-3	Aug. 2009 Feb. 2011–May. 2012	100	100	100	100	38	100	23	OXA-51, OXA-23, AMPC
195	31	1-3-3-2-2-96-3	Mar. 2013–Nov. 2014	100	100	100	100	97	100	100	OXA-51, OXA-23, AMPC
208	15	1-3-3-2-2-97-3	Jul. 2010–Oct. 2014	100	100	100	93	100	100	100	OXA-51, OXA-23, AMPC
218	2	1-3-3-2-2-102-3	Jul. 2011–Aug. 2011	100	100	100	100	100	100	0	OXA-51, OXA-23, AmpC
368	6	1-3-3-2-2-140-3	Jun. 2009–Sep. 2014	100	100	100	100	67	67	33	OXA-51, OXA-23, AmpC
369	1	1-3-3-2-2-106-3	Jun. 2013	100	100	100	100	0	100	-	OXA-51, OXA-23, AmpC
373	2	1-12-12-11-4-103-3	Mar. 2011, Apr. 2011	100	100	100	100	0	100	0	OXA-51, AmpC
383	2	1-12-56-1-4-149-45	Aug. 2011	100	100	100	100	100	100	100	OXA-51, AmpC
429	2	1-34-56-1-4-144-45	Jul. 2011, Sep. 2011	100	100	100	100	50	50	100	OXA-51, OXA-23, AmpC
469	6	1-12-3-2-2-103-3	Dec. 2012-Nov. 2013	100	100	100	100	100	100	100	OXA-51, OXA-23, AmpC
1302n	1	2-52-80-6-23-140-4	Jul. 2014	100	100	100	0	0	0	0	OXA-51, OXA-40, AmpC
1309n	1	27-155n-99-55-25 -270n-60	Aug. 2011	100	100	100	100	100	100	100	OXA-51, AmpC
Total	101	-	Jun. 2009–Nov. 2014	100	100	100	98	80	96	68	-

ⁿNovel; IPM imipenem, TZP piperacillin/tazobactam, TCC ticarcillin/clavulanic acid, CAZ ceftazidime, AMK amikacin, LVX levofloxacin, MNO minocycline